Colossal Biosciences said it has acquired Viagen Pets & Equine, a cloning and reproductive services company that maintains a biobank spanning more than 40 species, including endangered animals. The transaction brings Viagen’s cloning expertise and cryobanking infrastructure into Colossal’s platform for gene‑editing and species preservation, and the firm said Viagen will continue operating from its Austin headquarters with its existing staff. Colossal founder Ben Lamm described Viagen’s cloning stack as an industry standard that bolsters Colossal’s ambitions around de‑extinction and conservation. Financial terms were not disclosed; the acquisition follows Colossal’s expansion of a Series C round that raised the round’s total to $320 million. The deal merges cloning and biobanking capabilities with Colossal’s gene‑editing platform, accelerating its ability to preserve genetic diversity and to pursue conservation applications.